0001213900-26-087508 | 10-Q | XBRL Viewer

Print Document

Stockholders’ Equity - Schedule of Warrants to Acquire Shares of Common Stock (Details)	6 Months Ended
	Jun. 30, 2026 $ / shares shares
Schedule of Warrants to Acquire Shares of Common Stock [Line Items]
Number of Warrants Outstanding	13,518,652
Granted
Exercised	370,000
Expired	9,748,380
Number of Warrants Outstanding	3,400,272
April 2024 Common Warrants [Member]
Schedule of Warrants to Acquire Shares of Common Stock [Line Items]
Number of Warrants Outstanding	10,118,380
Granted
Exercised	370,000
Expired	9,748,380
Number of Warrants Outstanding
Exercise Price per Share (in Dollars per share) \| $ / shares	$ 5.25
April 2024 Pre-Funded Warrants [Member]
Schedule of Warrants to Acquire Shares of Common Stock [Line Items]
Number of Warrants Outstanding	1,700,000
Granted
Exercised
Expired
Number of Warrants Outstanding	1,700,000
Exercise Price per Share (in Dollars per share) \| $ / shares	$ 0.001
December 2024 Pre-Funded Warrants [Member]
Schedule of Warrants to Acquire Shares of Common Stock [Line Items]
Number of Warrants Outstanding	1,700,272
Granted
Exercised
Expired
Number of Warrants Outstanding	1,700,272
Exercise Price per Share (in Dollars per share) \| $ / shares	$ 0.001

Organization and Nature of the Business	6 Months Ended
Jun. 30, 2026
Organization and Nature of the Business [Abstract]
Organization and Nature of the Business	1. Organization and Nature of the Business *Overview* Protara Therapeutics, Inc., and its consolidated subsidiaries, or Protara or the Company, is a clinical-stage biopharmaceutical company committed to advancing transformative therapies for the treatment of cancer and rare diseases. Protara’s portfolio includes two development programs utilizing TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer, or NMIBC, and lymphatic malformations, or LMs. Additionally, the Company’s portfolio includes Intravenous, or IV, Choline Chloride, an investigational phospholipid substrate replacement therapy in development for patients receiving parenteral support, or PS. *Liquidity and Capital Resources* The Company is in the business of developing biopharmaceuticals and has no current or near-term revenues. The Company has incurred substantial clinical and other costs in its drug development efforts. The Company will need to raise additional capital in order to fully realize management’s plans. The Company believes that its current financial resources are sufficient to satisfy the Company’s estimated liquidity needs for at least 12 months from the date of issuance of these unaudited condensed consolidated financial statements.

Organization and Nature of the Business

6 Months Ended

Jun. 30, 2026

Organization and Nature of the Business [Abstract]

Organization and Nature of the Business

1. Organization and Nature of the Business

Overview

Protara Therapeutics, Inc., and its consolidated subsidiaries, or Protara or the Company, is a clinical-stage biopharmaceutical company committed to advancing transformative therapies for the treatment of cancer and rare diseases. Protara’s portfolio includes two development programs utilizing TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer, or NMIBC, and lymphatic malformations, or LMs. Additionally, the Company’s portfolio includes Intravenous, or IV, Choline Chloride, an investigational phospholipid substrate replacement therapy in development for patients receiving parenteral support, or PS.

Liquidity and Capital Resources

The Company is in the business of developing biopharmaceuticals and has no current or near-term revenues. The Company has incurred substantial clinical and other costs in its drug development efforts. The Company will need to raise additional capital in order to fully realize management’s plans.

The Company believes that its current financial resources are sufficient to satisfy the Company’s estimated liquidity needs for at least 12 months from the date of issuance of these unaudited condensed consolidated financial statements.

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Statement of Cash Flows [Abstract]
Public Offering, net of offering costs	$ 0	$ 214

Stock-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2026	Jun. 30, 2025	Jun. 12, 2026	Dec. 31, 2025	Jun. 11, 2025	Mar. 03, 2025	Jun. 07, 2024	Mar. 26, 2020
Amended and Restated 2014 Plan [Member]
Stock-Based Compensation [Line Items]
Shares authorized	4,474,683	4,474,683
Common stock subject to outstanding awards	3,221,520	3,221,520
2017 Equity Incentive Plan [Member]
Stock-Based Compensation [Line Items]
Shares authorized	2,000,000	2,000,000
Common stock subject to outstanding awards	134,328	134,328
2020 Plan [Member]
Stock-Based Compensation [Line Items]
Shares authorized							1,200,000		600,000
Common stock subject to outstanding awards	980,098	980,098
Increase in number of shares authorized							600,000
Available for grant	185,740	185,740
2024 Equity Incentive Plan [Member]
Stock-Based Compensation [Line Items]
Shares authorized				9,300,000		4,300,000		1,500,000
Common stock subject to outstanding awards	4,129,936	4,129,936
Increase in number of shares authorized				5,000,000		2,800,000
Common stock available for future issuance	5,093,541	5,093,541
2024 Employee Stock Purchase Plan [Member]
Stock-Based Compensation [Line Items]
Shares authorized								1,000,000
Available for grant	1,000,000	1,000,000
Number of shares issued under ESPP
Restricted Stock Units [Member]
Stock-Based Compensation [Line Items]
Unrecognized share based compensation (in Dollars)	$ 2,549	$ 2,549
Recognized over a weighted average period		2 years 1 month 2 days
Unsettled vested shares	289,500	289,500			289,500
Shares issued connection with settlement of RSUs		166,198
Number of shares settled		217,475
Net share settlement (in Dollars)		$ 298
Weighted average grant fair value per share (in Dollars per share)		$ 5.02
Stock Option [Member]
Stock-Based Compensation [Line Items]
Unrecognized share based compensation (in Dollars)	$ 10,873	$ 10,873
Recognized over a weighted average period		2 years 8 months 19 days
Intrinsic value of options (in Dollars)		$ 485
Weighted average grant fair value per share (in Dollars per share)		$ 3.46	$ 3.02

Other Assets

6 Months Ended

Jun. 30, 2026

Other Assets [Abstract]

Other Assets

6. Other Assets

Other assets consist of the following:

	As of
	June 30, 2026		December 31, 2025
Prepaid research and development, non-current	$	5,846	$	2,930
Other non-current assets		74		20
Total	$	5,920	$	2,950

Marketable Debt Securities (Tables)

6 Months Ended

Jun. 30, 2026

Marketable Debt Securities [Abstract]

Schedule of Marketable Debt Securities

Marketable debt securities, all of which were classified as available-for-sale, consist of the following:

	As of June 30, 2026
	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
Marketable debt securities:
Corporate bonds	$	109,672	$	6	$	(224	)	$	109,454
Commercial paper		10,965		-		(3	)		10,962
U.S. Treasury securities		5,000		2		-			5,002
Marketable debt securities, non-current:
Corporate bonds		19,500		-		(144	)		19,356
Total	$	145,137	$	8	$	(371	)	$	144,774

	As of December 31, 2025
	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
Marketable debt securities:
Corporate bonds	$	83,291	$	77	$	(22	)	$	83,346
U.S. Treasury securities		22,493		58		-			22,551
Marketable debt securities, non-current:
Corporate bonds		42,359		11		(34	)		42,336
Total	$	148,143	$	146	$	(56	)	$	148,233

Schedule of Marketable Debt Securities in a Loss Position

Marketable debt securities in a loss position consist of the following:

	As of June 30, 2026
	In Continuous Loss Position Less Than 12 Months					In Continuous Loss Position Greater Than 12 Months				Total
	Estimated Fair Value		Unrealized Losses			Estimated Fair Value		Unrealized Losses		Estimated Fair Value		Unrealized Losses
Marketable debt securities:
Corporate bonds	$	95,855	$	(224	)	$	-	$	-	$	95,855	$	(224	)
Commercial paper		10,962		(3	)		-		-		10,962		(3	)
Marketable debt securities, non-current:
Corporate bonds		19,356		(144	)		-		-		19,356		(144	)
Total	$	126,173	$	(371	)	$	-	$	-	$	126,173	$	(371	)

	As of December 31, 2025
	In Continuous Loss Position Less Than 12 Months					In Continuous Loss Position Greater Than 12 Months				Total
	Estimated Fair Value		Unrealized Losses			Estimated Fair Value		Unrealized Losses		Estimated Fair Value		Unrealized Losses
Marketable debt securities:
Corporate bonds	$	24,034	$	(22	)	$	-	$	-	$	24,034	$	(22	)
Marketable debt securities, non-current:
Corporate bonds		29,824		(34	)		-		-		29,824		(34	)
Total	$	53,858	$	(56	)	$	-	$	-	$	53,858	$	(56	)

Schedule of Interest and Investment Income

Interest and investment income (expense) consist of the following:

	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2026		2025		2026		2025
Interest income	$	1,480	$	1,223	$	3,136	$	2,778
Accretion of discount (Amortization of premium), net		170		389		353		555
Dividend income		6		14		14		22
Total	$	1,656	$	1,626	$	3,503	$	3,355

Stockholders’ Equity (Tables)

6 Months Ended

Jun. 30, 2026

Stockholders’ Equity [Abstract]

Schedule of Warrants to Acquire Shares of Common Stock

The following is a summary of the activity of the Company’s warrants to acquire shares of common stock for the six months ended June 30, 2026:

Equity Instrument	Outstanding, December 31, 2025		Granted		Exercised		Expired		Outstanding, June 30, 2026		Exercise Price per Share
April 2024 Common Warrants		10,118,380		-		370,000		9,748,380		-	$	5.250
April 2024 Pre-Funded Warrants		1,700,000		-		-		-		1,700,000	$	0.001
December 2024 Pre-Funded Warrants		1,700,272		-		-		-		1,700,272	$	0.001
Total		13,518,652		-		370,000		9,748,380		3,400,272

Leases - Schedule of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Schedule of Lease Expense [Abstract]
Operating lease expense	$ 338	$ 338	$ 676	$ 676
Total	$ 338	$ 338	$ 676	$ 676

Marketable Debt Securities (Details) - USD ($)	3 Months Ended		6 Months Ended
Marketable Debt Securities (Details) - USD ($)	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Marketables Debt Securities [Abstract]
Realized gains and losses

Other Assets - Schedule of Other Assets Consists (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Other Assets [Abstract]
Prepaid research and development, non-current	$ 5,846	$ 2,930
Other non-current assets	74	20
Total	$ 5,920	$ 2,950

- Definition

Amount of assets classified as other.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-7

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-14

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-11

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

+ Details

Marketable Debt Securities - Schedule of Marketable Debt Securities in a Loss Position (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2026	Dec. 31, 2025
Schedule of Marketable Debt Securities in a Loss Position [Line Items]
Estimated Fair Value	$ 126,173	$ 53,858
Unrealized Losses	(371)	(56)
Corporate Bonds-Marketable Debt Securities [Member]
Schedule of Marketable Debt Securities in a Loss Position [Line Items]
Estimated Fair Value	95,855	24,034
Unrealized Losses	(224)	(22)
Commercial paper- Marketable Debt Securities [Member]
Schedule of Marketable Debt Securities in a Loss Position [Line Items]
Estimated Fair Value	10,962
Unrealized Losses	(3)
Corporate bonds - Marketable Debt Securities Non-current [Member]
Schedule of Marketable Debt Securities in a Loss Position [Line Items]
Estimated Fair Value	19,356	29,824
Unrealized Losses	(144)	(34)
In Continuous Loss Position Less Than 12 Months [Member]
Schedule of Marketable Debt Securities in a Loss Position [Line Items]
Estimated Fair Value	126,173	53,858
Unrealized Losses	(371)	(56)
In Continuous Loss Position Less Than 12 Months [Member] \| Corporate Bonds-Marketable Debt Securities [Member]
Schedule of Marketable Debt Securities in a Loss Position [Line Items]
Estimated Fair Value	95,855	24,034
Unrealized Losses	(224)	(22)
In Continuous Loss Position Less Than 12 Months [Member] \| Commercial paper- Marketable Debt Securities [Member]
Schedule of Marketable Debt Securities in a Loss Position [Line Items]
Estimated Fair Value	10,962
Unrealized Losses	(3)
In Continuous Loss Position Less Than 12 Months [Member] \| Corporate bonds - Marketable Debt Securities Non-current [Member]
Schedule of Marketable Debt Securities in a Loss Position [Line Items]
Estimated Fair Value	19,356	29,824
Unrealized Losses	(144)	(34)
In Continuous Loss Position Greater Than 12 Months [Member]
Schedule of Marketable Debt Securities in a Loss Position [Line Items]
Estimated Fair Value
Unrealized Losses
In Continuous Loss Position Greater Than 12 Months [Member] \| Corporate Bonds-Marketable Debt Securities [Member]
Schedule of Marketable Debt Securities in a Loss Position [Line Items]
Estimated Fair Value
Unrealized Losses
In Continuous Loss Position Greater Than 12 Months [Member] \| Commercial paper- Marketable Debt Securities [Member]
Schedule of Marketable Debt Securities in a Loss Position [Line Items]
Estimated Fair Value
Unrealized Losses
In Continuous Loss Position Greater Than 12 Months [Member] \| Corporate bonds - Marketable Debt Securities Non-current [Member]
Schedule of Marketable Debt Securities in a Loss Position [Line Items]
Estimated Fair Value
Unrealized Losses

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (fff)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (ff)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-3

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-3

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-3

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aa)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aaa)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

+ Details

Marketable Debt Securities - Schedule of Marketable Debt Securities (Details) - Marketable Debt Securities [Member] - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2026	Dec. 31, 2025
Schedule of Available For Sale Securities [Line Items]
Amortized Cost	$ 145,137	$ 148,143
Unrealized Gains	8	146
Unrealized Losses	(371)	(56)
Estimated Fair Value	144,774	148,233
Corporate bonds - presented in marketable debt securities [Member]
Schedule of Available For Sale Securities [Line Items]
Amortized Cost	109,672	83,291
Unrealized Gains	6	77
Unrealized Losses	(224)	(22)
Estimated Fair Value	109,454	83,346
Commercial paper - presented in marketable debt securities [Member]
Schedule of Available For Sale Securities [Line Items]
Amortized Cost	10,965
Unrealized Gains
Unrealized Losses	(3)
Estimated Fair Value	10,962
U.S. Treasury securities - presented in marketable debt securities [Member]
Schedule of Available For Sale Securities [Line Items]
Amortized Cost	5,000	22,493
Unrealized Gains	2	58
Unrealized Losses
Estimated Fair Value	5,002	22,551
Corporate bonds - presented in marketable debt securities, Non-current [Member]
Schedule of Available For Sale Securities [Line Items]
Amortized Cost	19,500	42,359
Unrealized Gains		11
Unrealized Losses	(144)	(34)
Estimated Fair Value	$ 19,356	$ 42,336

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2026

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

The Company’s significant accounting policies are disclosed in the audited consolidated financial statements and the notes thereto in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the United States Securities and Exchange Commission, or SEC, on March 10, 2026, or the Annual Report on Form 10-K. There were no changes to the Company’s significant accounting policies as described in the Annual Report on Form 10-K.

Basis of Presentation

The accompanying condensed consolidated financial statements and the related disclosures as of June 30, 2026 and for the three and six months ended June 30, 2026 and 2025 are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, and the rules and regulations of the SEC, for interim financial statements. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These interim condensed consolidated financial statements should be read in conjunction with the 2025 audited consolidated financial statements and notes included in the Annual Report on Form 10-K. The December 31, 2025 consolidated balance sheet included herein was derived from the audited financial statements as of that date but does not include all disclosures including notes required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company’s financial position and results of operations for the three and six months ended June 30, 2026 and 2025. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year ending December 31, 2026 or any other interim period or future year or period.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in the accompanying condensed consolidated financial statements.

Recent Accounting Pronouncements Not Yet Adopted

In November 2024, the Financial Accounting Standards Board, or the FASB, issued ASU 2024-03 – Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures, which enhances the disclosures for various types of expenses. The standard is effective for public companies for annual periods beginning after December 15, 2026. Early adoption is available. The Company is still evaluating the full extent of the potential impact of the adoption of ASU 2024-03.

Subsequent Events

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were available to be issued. The Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

Net Income (Loss) per Common Share (Tables)

6 Months Ended

Jun. 30, 2026

Net Income (Loss) per Common Share [Abstract]

Schedule of Net Income (Loss) Per Share Attributable to Common Stockholders, Basic and Diluted

The following table sets forth the computation of the net income (loss) per share attributable to common stockholders, basic and diluted:

	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2026			2025			2026			2025
Numerator
Net income (loss) attributable to common stockholders	$	(21,668	)	$	(14,960	)	$	(39,450	)	$	(26,874	)
Denominator
Weighted-average shares of common stock outstanding, basic and diluted		61,006,766			42,270,855			59,282,380			41,493,714
Net income (loss) per share attributable to common stockholders, basic and diluted	$	(0.36	)	$	(0.35	)	$	(0.67	)	$	(0.65	)

Schedule of Anti-Dilutive Effect

The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net income (loss) per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:

	As of June 30,
	2026		2025
Potentially dilutive shares:
Stock options		7,476,614		5,563,027
Series 1 Convertible Preferred Stock		872,183		5,616,973
Restricted stock units		699,768		510,945
April 2024 Common Warrants		-		10,118,380
Total		9,048,565		21,809,325

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Accrued Expenses and Other Current Liabilities [Abstract]
Research and development	$ 4,149	$ 2,683
Employee costs	2,690	3,267
Other expenses	531	279
Total	$ 7,370	$ 6,229

Stockholders’ Equity (Details) $ / shares in Units, $ in Thousands		3 Months Ended	6 Months Ended
	May 13, 2026 USD ($)	Jun. 30, 2026 $ / shares shares	Jun. 30, 2026 $ / shares shares	Jun. 12, 2026 shares	Jun. 11, 2026 shares	Dec. 31, 2025 $ / shares shares
Stockholders’ Equity [Line Items]
Common stock, shares authorized		200,000,000	200,000,000	200,000,000	100,000,000	100,000,000
Common stock, par value (in Dollars per share) \| $ / shares		$ 0.001	$ 0.001			$ 0.001
Common stock, shares issued		59,083,935	59,083,935			53,587,260
Common stock, shares outstanding		59,083,935	59,083,935			53,587,260
Preferred stock, shares authorized		10,000,000	10,000,000			10,000,000
Preferred stock, par value (in Dollars per share) \| $ / shares		$ 0.001	$ 0.001			$ 0.001
April 2024 Common Warrants [Member]
Stockholders’ Equity [Line Items]
Exercise price per share (in Dollars per share) \| $ / shares		$ 5.25	$ 5.25
December Pre-Funded Warrant [Member]
Stockholders’ Equity [Line Items]
Warrants to purchase common stock		2,325,372	2,325,372
April 2024 Private Placement [Member] \| April 2024 Common Warrants [Member]
Stockholders’ Equity [Line Items]
Warrants to purchase common stock		10,843,380	10,843,380
April 2024 Private Placement [Member] \| April Pre-Funded Warrant [Member]
Stockholders’ Equity [Line Items]
Warrants to purchase common stock		1,700,000	1,700,000
Common Stock [Member]
Stockholders’ Equity [Line Items]
Number of vote per share			one
Shares converted		3,773,586	4,744,790
2026 ATM Program [Member]
Stockholders’ Equity [Line Items]
Aggregate offering price (in Dollars) \| $	$ 100,000
Number of shares sold under the ATM program		0	0
Series 1 Convertible Preferred Stock [Member]
Stockholders’ Equity [Line Items]
Preferred stock, shares authorized		8,028	8,028			8,028
Preferred stock, shares issued		872	872			5,615
Preferred stock, shares outstanding		872	872			5,615
Preferred stock convertible conversion ratio		1,000	1,000
Preferred stock, liquidation preference per share (in Dollars per share) \| $ / shares		$ 7.01	$ 7.01
Shares converted		3,772	4,743

Leases (Tables)

6 Months Ended

Jun. 30, 2026

Leases [Abstract]

Schedule of Lease Expense

Lease expense consists of the following:

	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2026		2025		2026		2025
Operating lease expense	$	338	$	338	$	676	$	676
Total	$	338	$	338	$	676	$	676

Schedule of Weighted Average Discount Rate and Weighted-Average Remaining Lease Term for Operating Leases

The weighted average discount rate and weighted-average remaining lease term for operating leases were:

	As of June 30, 2026
Weighted-average discount rate		7.0	%
Weighted-average remaining lease term – operating lease (in months)		25

Schedule of Annual Minimum Lease Payments of the Company’s Operating Lease Liabilities

As of June 30, 2026, the expected annual minimum lease payments of the Company’s operating lease liabilities were as follows:

For the year ending December 31:	Operating Lease Payments
2026 (excluding the six months ended June 30, 2026)	$	715
2027		1,429
2028		718
2029		87
Thereafter		-
Total future operating lease payments		2,949
Less: imputed interest		200
Present value of future minimum lease payments	$	2,749

Fair Value of Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2026

Fair Value of Financial Instruments [Abstract]

Schedule of Financial Instruments that are Measured and Carried at Fair Value on a Recurring Basis

The accounting policies of fair value measurements are the same as those described in Part II, Item 8, “Financial Statements and Supplementary Data—Summary of Significant Accounting Policies” in the Company’s Annual Report on Form 10-K:

	As of June 30, 2026
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents:
Money market funds^(a)	$	16,565	$	-	$	-	$	16,565
Restricted cash, non-current:
Money market funds^(b)		745		-		-		745
Marketable debt securities:
Corporate bonds^(c)		-		128,810		-		128,810
Commercial paper^(c)		-		10,962		-		10,962
U.S. Treasury securities^(c)		5,002		-		-		5,002
Total	$	22,312	$	139,772	$	-	$	162,084

	As of December 31, 2025
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents:
Money market funds^(a)	$	45,355	$	-	$	-	$	45,355
Corporate bonds^(a)		-		3,704		-		3,704
Restricted cash, non-current:
Money market funds^(b)		745		-		-		745
Marketable debt securities:
Corporate bonds^(c)		-		125,682		-		125,682
U.S. Treasury securities^(c)		22,551		-		-		22,551
Total	$	68,651	$	129,386	$	-	$	198,037

(a)	Money market funds and corporate bonds with original maturities of 90 days or less are included within cash and cash equivalents in the condensed consolidated balance sheets.

(b)	Restricted money market funds are included within restricted cash, non-current in the condensed consolidated balance sheets.

(c)

Corporate bonds, commercial paper and U.S. Treasury securities with original maturities greater than 90 days are included within marketable debt securities in the condensed consolidated balance sheets and classified as current or non-current based upon whether the maturity of the financial asset is less than or greater than 12 months.

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid research and development	$ 1,079	$ 1,926
Accrued interest on marketable debt securities	1,277	1,257
Proceeds in transit in connection with stock option exercise	412
Prepaid insurance	166	355
Prepaid software	253	115
Other prepaid expenses	241	232
Other current assets	230	65
Total	$ 3,658	$ 3,950

Stock-Based Compensation - Schedule of Stock Option Activity (Details) - Stock Options [Member]
$ / shares in Units, $ in Thousands

6 Months Ended

12 Months Ended

Jun. 30, 2026

USD ($)

$ / shares

Dec. 31, 2025

USD ($)

$ / shares

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Number of Options, Balance | shares

5,693,891

Weighted Average Exercise Price, Balance | $ / shares

$ 6.3

Weighted Average Remaining Contractual Term (years), Balance

7 years 7 months 28 days

7 years 6 months 3 days

Aggregate Intrinsic Value, Balance | $

$ 8,982

^[1]

Number of Options, Granted | shares

2,307,560

Weighted Average Exercise Price, Granted | $ / shares

$ 4.89

Number of Options, Exercised | shares

(215,687)

Weighted Average Exercise Price, Exercised | $ / shares

$ 1.91

Number of Options, Forfeited | shares

(309,150)

Weighted Average Exercise Price, Forfeited | $ / shares

$ 4.57

Number of Options, Expired | shares

Weighted Average Exercise Price, Expired | $ / shares

Number of Options, Balance | shares

7,476,614

Weighted Average Exercise Price, Balance | $ / shares

$ 6.06

Aggregate Intrinsic Value, Balance | $

$ 2,987

^[1]

Number of Options, Vested and expected to vest | shares

7,476,614

Weighted Average Exercise Price, Vested and expected to vest | $ / shares

$ 6.06

Weighted Average Remaining Contractual Term (years), Vested and expected to vest

7 years 7 months 28 days

Aggregate Intrinsic Value, Vested and expected to vest | $

$ 2,987

^[1]

Number of Options, Balance | shares

3,668,578

Weighted Average Exercise Price, Balance | $ / shares

$ 7.9

Weighted Average Remaining Contractual Term (years), Balance

6 years 3 months 7 days

Aggregate Intrinsic Value, Balance | $

$ 1,858

^[1]

[1]	Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on December 31, 2025 and June 30, 2026, respectively. The intrinsic value of options exercised during the six months ended June 30, 2026 was $485

Commitments and Contingencies

6 Months Ended

Jun. 30, 2026

Commitments and Contingencies [Abstract]

Commitments and Contingencies

9. Commitments and Contingencies

Commitments

The Company has commitments under certain license and collaboration agreements, lease agreements and employment agreements. Commitments under certain license agreements primarily include annual payments, payments upon the achievement of certain milestones and royalty payments based on net sales of licensed products. Commitments under lease agreements consist of future minimum lease payments for operating leases which are further described in Note 8 of this Quarterly Report on Form 10-Q.

Contingencies

From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. Management is of the opinion that the ultimate outcome of these matters would not have a material adverse impact on the financial position of the Company or the results of its operations.

In the normal course of business, the Company enters into contracts in which it makes representations and warranties regarding the performance of its services and that its services will not infringe on third-party intellectual rights. There have been no significant events related to such representations and warranties in which the Company believes the outcome could result in losses or penalties in the future.

Leases - Schedule of Weighted Average Discount Rate and Weighted-Average Remaining Lease Term for Operating Leases (Details)	Jun. 30, 2026
Schedule of Weighted Average Discount Rate and Weighted-Average Remaining Lease Term for Operating Leases [Abstract]
Weighted-average discount rate	7.00%
Weighted-average remaining lease term – operating lease (in months)	25 months

Net Income (Loss) per Common Share - Schedule of Net Income (Loss) Per Share Attributable to Common Stockholders, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2026	Mar. 31, 2026	Jun. 30, 2025	Mar. 31, 2025	Jun. 30, 2026	Jun. 30, 2025
Numerator
Net income (loss) attributable to common stockholders	$ (21,668)	$ (17,782)	$ (14,960)	$ (11,914)	$ (39,450)	$ (26,874)
Denominator
Weighted-average shares of common stock outstanding, basic	61,006,766		42,270,855		59,282,380	41,493,714
Weighted-average shares of common stock outstanding, diluted	61,006,766		42,270,855		59,282,380	41,493,714
Net income (loss) per share attributable to common stockholders, basic	$ (0.36)		$ (0.35)		$ (0.67)	$ (0.65)
Net income (loss) per share attributable to common stockholders, diluted	$ (0.36)		$ (0.35)		$ (0.67)	$ (0.65)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482705/350-40-65-4

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479719/606-10-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482705/350-40-65-4

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479719/606-10-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482705/350-40-65-4

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479719/606-10-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (24)(d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 45: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 50: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 51: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 52: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation	$ 1,384	$ 903	$ 2,746	$ 1,736
Research and development [Member]: us-gaap:GeneralAndAdministrativeExpense
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation	1,020	677	1,970	1,318
Research and development [Member]: us-gaap:ResearchAndDevelopmentExpense
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation	$ 364	$ 226	$ 776	$ 418

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Leases

6 Months Ended

Jun. 30, 2026

Leases [Abstract]

Leases

8. Leases

Operating leases

Leases classified as operating leases are included in operating lease right-of-use, or ROU, assets, operating lease liabilities and operating lease liabilities, non-current, in the Company’s condensed consolidated balance sheets. Cash paid for operating lease liabilities during the six months ended June 30, 2026 and 2025 was $715 and $681, respectively.

Lease expense consists of the following:

	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2026		2025		2026		2025
Operating lease expense	$	338	$	338	$	676	$	676
Total	$	338	$	338	$	676	$	676

Variable lease expense for the three months ended June 30, 2026 and 2025 was $34 and $31, respectively. Variable lease expenses for the six months ended June 30, 2026 and 2025 were $66 and $62, respectively.

The weighted average discount rate and weighted-average remaining lease term for operating leases were:

	As of June 30, 2026
Weighted-average discount rate		7.0	%
Weighted-average remaining lease term – operating lease (in months)		25

As of June 30, 2026, the expected annual minimum lease payments of the Company’s operating lease liabilities were as follows:

For the year ending December 31:	Operating Lease Payments
2026 (excluding the six months ended June 30, 2026)	$	715
2027		1,429
2028		718
2029		87
Thereafter		-
Total future operating lease payments		2,949
Less: imputed interest		200
Present value of future minimum lease payments	$	2,749

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2026	Aug. 07, 2026
Document Information Line Items
Entity Central Index Key	0001359931
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2026
Document Fiscal Year Focus	2026
Document Transition Report	false
Entity File Number	001-36694
Entity Registrant Name	Protara Therapeutics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-4580525
Entity Address, Address Line One	345 Park Avenue South
Entity Address, Address Line Two	3rd Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10010
City Area Code	(646)
Local Phone Number	844-0337
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	TARA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		59,095,488
Amendment Flag	false
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31

Stock-Based Compensation - Schedule of Restricted Stock Unit Activity (Details) - Restricted Stock Unit [Member]	6 Months Ended
	Jun. 30, 2026 $ / shares shares
Restricted Stock Unit Activity [Line Items]
Restricted Stock Units, Non-vested Balance \| shares	571,145
Weighted Average Grant Date Fair Value, Non-vested Balance \| $ / shares	$ 3.57
Restricted Stock Units, Granted \| shares	427,180
Weighted Average Grant Date Fair Value, Granted \| $ / shares	$ 5.02
Restricted Stock Units, Forfeited \| shares	(81,082)
Weighted Average Grant Date Fair Value, Forfeited \| $ / shares	$ 4.38
Restricted Stock Units, Vested \| shares	(217,475)
Weighted Average Grant Date Fair Value, Vested \| $ / shares	$ 3.38
Restricted Stock Units, Non-vested Balance \| shares	699,768
Weighted Average Grant Date Fair Value, Non-vested Balance \| $ / shares	$ 4.42

Stock-Based Compensation

6 Months Ended

Jun. 30, 2026

Stock-Based Compensation [Abstract]

Stock-Based Compensation

11. Stock-Based Compensation

2014 Equity Incentive Plan

On October 3, 2014, the stockholders approved the 2014 Equity Incentive Plan. On June 20, 2017, the Company’s Board of Directors amended the 2014 Equity Incentive Plan, or the Amended and Restated 2014 Plan.

The Amended and Restated 2014 Plan, as amended, provides for the grant of incentive and non-statutory stock options, stock appreciation rights, restricted stock and stock unit awards, performance units, stock grants and qualified performance-based awards. The total number of shares authorized was 4,474,683 shares. As of June 7, 2024, in connection with the creation of the 2024 Equity Incentive Plan, or the 2024 Plan, no additional awards will be made under the Amended and Restated 2014 Plan, as amended.

As of June 30, 2026, there were 3,221,520 shares of common stock subject to outstanding awards under the Amended and Restated 2014 Plan, as amended.

2017 Equity Incentive Plan

On August 10, 2017, ArTara Subsidiary, Inc. (a predecessor of the Company), or Private ArTara, along with its Board of Directors and its stockholders approved the ArTara Therapeutics, Inc. 2017 Equity Incentive Plan, or the 2017 Plan, to enable Private ArTara and its affiliates to recruit and retain highly qualified personnel and to incentivize personnel for productivity and growth.

The total number of shares authorized under the 2017 Plan was 2,000,000 for the issuance of stock options, stock appreciation rights, restricted stock and restricted stock units, or RSUs, to among others, members of the Board of Directors, employees, consultants and service providers to the Company and its affiliates. As of January 9, 2020 no additional awards will be made under the 2017 Plan.

As of June 30, 2026, there were 134,328 shares of common stock subject to outstanding awards under the 2017 Plan.

2020 Inducement Plan

On March 26, 2020, the Compensation Committee of the Board of Directors, or the Compensation Committee, approved the 2020 Inducement Plan, or the 2020 Plan, in order to award non-statutory stock options, restricted stock awards, restricted stock unit awards and other stock-based awards to persons not previously an employee or director of the Company, or following a bona fide period of non-employment, as an inducement material to such persons entering into employment with the Company. The Compensation Committee also adopted a form of stock option grant notice and stock option agreement and forms of restricted stock unit grant notice and restricted stock unit agreement for use with the 2020 Plan.

The 2020 Plan provided for a total of 600,000 shares for the issuance of the Company’s common stock. On March 3, 2025, the Compensation Committee approved a Certificate of First Amendment to the 2020 Plan, or the Amended 2020 Plan, to increase the number of shares provided for under the Amended 2020 Plan by 600,000 shares to 1,200,000 shares.

As of June 30, 2026, there were 980,098 shares of common stock subject to outstanding awards and 185,740 shares of common stock available for future issuance under the Amended 2020 Plan.

2024 Equity Incentive Plan

On June 7, 2024, the stockholders approved the 2024 Plan. The 2024 Plan provided for the grant of 1,500,000 shares of common stock for stock options, stock appreciation rights, restricted stock, RSUs, performance units, performance shares and other stock and cash awards. On June 11, 2025, the stockholders approved an amendment to the 2024 Plan increasing the number of shares available for grant under the 2024 Plan by 2,800,000 shares to 4,300,000 shares. On June 12, 2026, the stockholders approved an amendment to the 2024 Plan, or the Amended 2024 Plan, increasing the number of shares available for grant under the Amended 2024 Plan by 5,000,000 shares to 9,300,000 shares.

Terms of the stock awards, including vesting requirements, are determined by the Board of Directors, or the Compensation Committee thereof, subject to the provisions of the Amended 2024 Plan.

As of June 30, 2026, there were 4,129,936 shares of common stock subject to outstanding awards and 5,093,541 shares of common stock available for future issuance under the Amended 2024 Plan.

2024 Employee Stock Purchase Plan

On June 7, 2024, the stockholders of the Company approved the 2024 Employee Stock Purchase Plan, or the 2024 ESPP. The number of shares authorized under the 2024 ESPP is 1,000,000.

As of June 30, 2026, the number of shares available for issuance under the 2024 ESPP was 1,000,000. During the three and six months ended June 30, 2026, no shares were issued under the 2024 ESPP.

Restricted Stock Units

The following table summarizes restricted stock unit activity for the six months ended June 30, 2026:

	Restricted Stock Units			Weighted Average Grant Date Fair Value
Non-vested as of December 31, 2025		571,145		$	3.57
Granted		427,180			5.02
Forfeited		(81,082	)		4.38
Vested		(217,475	)		3.38
Non-vested as of June 30, 2026		699,768		$	4.42

The fair value of RSUs is amortized on a straight-line basis over the requisite service period of the respective awards. As of June 30, 2026, the unamortized value of RSUs was $2,549. As of June 30, 2026, the weighted average remaining amortization period was 2.09 years. As of June 30, 2026 and December 31, 2025, 289,500 RSUs have vested but have not yet been settled into shares of the Company’s common stock.

During the six months ended June 30, 2026, the Company issued 166,198 shares of the Company’s common stock from the net settlement of 217,475 RSUs. The Company paid $298 in connection with the net share settlement of these RSUs.

Stock Options

The following table summarizes stock option activity for the six months ended June 30, 2026:

	Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value⁽¹⁾
Outstanding as of December 31, 2025		5,693,891		$	6.30		7.51	$	8,982
Granted		2,307,560			4.89
Exercised		(215,687	)		1.91
Forfeited		(309,150	)		4.57
Expired		-			-		-		-
Outstanding as of June 30, 2026		7,476,614		$	6.06		7.66	$	2,987

Vested and expected to vest at June 30, 2026		7,476,614		$	6.06		7.66	$	2,987
Exercisable as of June 30, 2026		3,668,578			7.90		6.27		1,858

(1)	Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on December 31, 2025 and June 30, 2026, respectively. The intrinsic value of options exercised during the six months ended June 30, 2026 was $485.

The weighted average grant date fair value per share of the options granted during the six months ended June 30, 2026 and 2025 was $3.46 and $3.02, respectively. As of June 30, 2026, there was approximately $10,873 of unrecognized stock-based compensation for unvested stock option grants, which is expected to be recognized over a weighted average period of 2.72 years. The total unrecognized stock-based compensation cost will be adjusted for actual forfeitures as they occur.

Summary of Stock-Based Compensation Expense

The following tables summarize total stock-based compensation costs recognized:

	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2026		2025		2026		2025
Stock options	$	1,090	$	736	$	2,135	$	1,448
Restricted stock units		294		167		611		288
Total	$	1,384	$	903	$	2,746	$	1,736

Stock-based compensation expense was reflected within the condensed consolidated statements of operations and comprehensive loss as:

	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2026		2025		2026		2025
General and administrative	$	1,020	$	677	$	1,970	$	1,318
Research and development		364		226		776		418
Total	$	1,384	$	903	$	2,746	$	1,736

Stock-Based Compensation - Schedule of Stock-Based Compensation Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation costs	$ 1,384	$ 903	$ 2,746	$ 1,736
Stock options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation costs	1,090	736	2,135	1,448
Restricted stock units [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation costs	$ 294	$ 167	$ 611	$ 288

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Accounting Policies, by Policy (Policies)	6 Months Ended
Accounting Policies, by Policy (Policies)	Jun. 30, 2026
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	*Basis of Presentation* The accompanying condensed consolidated financial statements and the related disclosures as of June 30, 2026 and for the three and six months ended June 30, 2026 and 2025 are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, and the rules and regulations of the SEC, for interim financial statements. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These interim condensed consolidated financial statements should be read in conjunction with the 2025 audited consolidated financial statements and notes included in the Annual Report on Form 10-K. The December 31, 2025 consolidated balance sheet included herein was derived from the audited financial statements as of that date but does not include all disclosures including notes required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company’s financial position and results of operations for the three and six months ended June 30, 2026 and 2025. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year ending December 31, 2026 or any other interim period or future year or period.
Principles of Consolidation	*Principles of Consolidation* The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in the accompanying condensed consolidated financial statements.
Recent Accounting Pronouncements Not Yet Adopted	*Recent Accounting Pronouncements Not Yet Adopted* In November 2024, the Financial Accounting Standards Board, or the FASB, issued ASU 2024-03 – Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures, which enhances the disclosures for various types of expenses. The standard is effective for public companies for annual periods beginning after December 15, 2026. Early adoption is available. The Company is still evaluating the full extent of the potential impact of the adoption of ASU 2024-03.
Subsequent Events	*Subsequent Events* The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were available to be issued. The Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

Leases (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Leases (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Leases [Abstract]
Cash paid for operating lease liabilities			$ 715	$ 681
Variable lease expenses	$ 34	$ 31	$ 66	$ 62

Leases - Schedule of Annual Minimum Lease Payments of the Company’s Operating Lease Liabilities (Details) $ in Thousands	Jun. 30, 2026 USD ($)
Schedule of Annual Minimum Lease Payments of the Company’s Operating Lease Liabilities [Abstract]
2026 (excluding the six months ended June 30, 2026)	$ 715
2027	1,429
2028	718
2029	87
Thereafter
Total future operating lease payments	2,949
Less: imputed interest	200
Present value of future minimum lease payments	$ 2,749

Net Income (Loss) per Common Share

6 Months Ended

Jun. 30, 2026

Net Income (Loss) per Common Share [Abstract]

Net Income (Loss) per Common Share

12. Net Income (Loss) per Common Share

The following table sets forth the computation of the net income (loss) per share attributable to common stockholders, basic and diluted:

	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2026			2025			2026			2025
Numerator
Net income (loss) attributable to common stockholders	$	(21,668	)	$	(14,960	)	$	(39,450	)	$	(26,874	)
Denominator
Weighted-average shares of common stock outstanding, basic and diluted		61,006,766			42,270,855			59,282,380			41,493,714
Net income (loss) per share attributable to common stockholders, basic and diluted	$	(0.36	)	$	(0.35	)	$	(0.67	)	$	(0.65	)

The weighted-average number of shares of common stock outstanding during the period includes any contingently issuable shares for which there is no circumstance under which those shares would not be issued and shares issuable upon the exercise of warrants to purchase common stock for no or nominal consideration. This includes 289,500 RSUs that have vested but that have not yet been settled into shares of the Company’s common stock, 1,700,000 April 2024 Pre-Funded Warrants and 1,700,272 December 2024 Pre-Funded Warrants.

Since the Company was in a net loss position for all periods presented, net income (loss) per share attributable to common stockholders was the same, on a basic and diluted basis, as the inclusion of all potential common equivalent shares outstanding would have been anti-dilutive. The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each period end, from the computation of diluted net income (loss) per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:

	As of June 30,
	2026		2025
Potentially dilutive shares:
Stock options		7,476,614		5,563,027
Series 1 Convertible Preferred Stock		872,183		5,616,973
Restricted stock units		699,768		510,945
April 2024 Common Warrants		-		10,118,380
Total		9,048,565		21,809,325

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2026

Stock-Based Compensation [Abstract]

Schedule of Restricted Stock Unit Activity

The following table summarizes restricted stock unit activity for the six months ended June 30, 2026:

	Restricted Stock Units			Weighted Average Grant Date Fair Value
Non-vested as of December 31, 2025		571,145		$	3.57
Granted		427,180			5.02
Forfeited		(81,082	)		4.38
Vested		(217,475	)		3.38
Non-vested as of June 30, 2026		699,768		$	4.42

Schedule of Stock Option Activity

The following table summarizes stock option activity for the six months ended June 30, 2026:

	Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value⁽¹⁾
Outstanding as of December 31, 2025		5,693,891		$	6.30		7.51	$	8,982
Granted		2,307,560			4.89
Exercised		(215,687	)		1.91
Forfeited		(309,150	)		4.57
Expired		-			-		-		-
Outstanding as of June 30, 2026		7,476,614		$	6.06		7.66	$	2,987

Vested and expected to vest at June 30, 2026		7,476,614		$	6.06		7.66	$	2,987
Exercisable as of June 30, 2026		3,668,578			7.90		6.27		1,858

(1)	Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on December 31, 2025 and June 30, 2026, respectively. The intrinsic value of options exercised during the six months ended June 30, 2026 was $485.

Schedule of Stock-Based Compensation Costs

The following tables summarize total stock-based compensation costs recognized:

	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2026		2025		2026		2025
Stock options	$	1,090	$	736	$	2,135	$	1,448
Restricted stock units		294		167		611		288
Total	$	1,384	$	903	$	2,746	$	1,736

Schedule of Stock-Based Compensation Expense

Stock-based compensation expense was reflected within the condensed consolidated statements of operations and comprehensive loss as:

	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2026		2025		2026		2025
General and administrative	$	1,020	$	677	$	1,970	$	1,318
Research and development		364		226		776		418
Total	$	1,384	$	903	$	2,746	$	1,736

Marketable Debt Securities

6 Months Ended

Jun. 30, 2026

Marketable Debt Securities [Abstract]

Marketable Debt Securities

4. Marketable Debt Securities

Marketable debt securities, all of which were classified as available-for-sale, consist of the following:

	As of June 30, 2026
	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
Marketable debt securities:
Corporate bonds	$	109,672	$	6	$	(224	)	$	109,454
Commercial paper		10,965		-		(3	)		10,962
U.S. Treasury securities		5,000		2		-			5,002
Marketable debt securities, non-current:
Corporate bonds		19,500		-		(144	)		19,356
Total	$	145,137	$	8	$	(371	)	$	144,774

	As of December 31, 2025
	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
Marketable debt securities:
Corporate bonds	$	83,291	$	77	$	(22	)	$	83,346
U.S. Treasury securities		22,493		58		-			22,551
Marketable debt securities, non-current:
Corporate bonds		42,359		11		(34	)		42,336
Total	$	148,143	$	146	$	(56	)	$	148,233

The Company has recorded the securities at fair value in its condensed consolidated balance sheets and unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss). For the three and six months ended June 30, 2026 and 2025 there were no realized gains or losses. Gains, if any, would be included in investment income within the condensed consolidated statements of operations and comprehensive loss.

The remaining maturities of all debt securities held at June 30, 2026 was less than five years. There were no sales of securities in the periods presented.

Credit Losses

Securities with an amortized cost basis in excess of estimated fair value are assessed to determine what amount of the excess, if any, is caused by expected credit losses.

Marketable debt securities in a loss position consist of the following:

	As of June 30, 2026
	In Continuous Loss Position Less Than 12 Months					In Continuous Loss Position Greater Than 12 Months				Total
	Estimated Fair Value		Unrealized Losses			Estimated Fair Value		Unrealized Losses		Estimated Fair Value		Unrealized Losses
Marketable debt securities:
Corporate bonds	$	95,855	$	(224	)	$	-	$	-	$	95,855	$	(224	)
Commercial paper		10,962		(3	)		-		-		10,962		(3	)
Marketable debt securities, non-current:
Corporate bonds		19,356		(144	)		-		-		19,356		(144	)
Total	$	126,173	$	(371	)	$	-	$	-	$	126,173	$	(371	)

	As of December 31, 2025
	In Continuous Loss Position Less Than 12 Months					In Continuous Loss Position Greater Than 12 Months				Total
	Estimated Fair Value		Unrealized Losses			Estimated Fair Value		Unrealized Losses		Estimated Fair Value		Unrealized Losses
Marketable debt securities:
Corporate bonds	$	24,034	$	(22	)	$	-	$	-	$	24,034	$	(22	)
Marketable debt securities, non-current:
Corporate bonds		29,824		(34	)		-		-		29,824		(34	)
Total	$	53,858	$	(56	)	$	-	$	-	$	53,858	$	(56	)

As of June 30, 2026 and December 31, 2025, it was determined that there were no expected credit losses.

Interest and Investment Income (Expense)

Interest and investment income (expense) consist of the following:

	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2026		2025		2026		2025
Interest income	$	1,480	$	1,223	$	3,136	$	2,778
Accretion of discount (Amortization of premium), net		170		389		353		555
Dividend income		6		14		14		22
Total	$	1,656	$	1,626	$	3,503	$	3,355

Net Income (Loss) per Common Share (Details)	6 Months Ended
Net Income (Loss) per Common Share (Details)	Jun. 30, 2026 shares
Net Income (Loss) Per Common Share [Line Items]
Restricted stock unit vested	289,500
April2024 Pre-Funded Warrants [Member]
Net Income (Loss) Per Common Share [Line Items]
Pre-funded warrants	1,700,000
December2024 Pre-Funded Warrants [Member]
Net Income (Loss) Per Common Share [Line Items]
Pre-funded warrants	1,700,272

Net Income (Loss) per Common Share - Schedule of Anti-Dilutive Effect (Details) - shares	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Schedule of Anti-Dilutive Effect [Line Items]
Total potentially dilutive shares	9,048,565	21,809,325
Stock options [Member]
Schedule of Anti-Dilutive Effect [Line Items]
Total potentially dilutive shares	7,476,614	5,563,027
Series 1 Convertible Preferred Stock [Member]
Schedule of Anti-Dilutive Effect [Line Items]
Total potentially dilutive shares	872,183	5,616,973
Restricted stock units [Member]
Schedule of Anti-Dilutive Effect [Line Items]
Total potentially dilutive shares	699,768	510,945
April 2024 Common Warrants [Member]
Schedule of Anti-Dilutive Effect [Line Items]
Total potentially dilutive shares		10,118,380

Segment Information (Details)	6 Months Ended
Segment Information (Details)	Jun. 30, 2026 segment
Segment Information [Abstract]
Segment reporting description	The Company’s Chief Executive Officer is the chief operating decision maker, or CODM. The CODM allocates resources and assesses performance of the Company’s single reportable segment by regularly reviewing the segment net income (loss) that also is reported on the condensed consolidated statements of operations and comprehensive loss as consolidated net income (loss). The measure of segment assets is reported on the balance sheet as total consolidated assets.
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]	Chief Executive Officer
Reportable segment	1

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 17,076	$ 49,657
Marketable debt securities	125,418	105,897
Prepaid expenses and other current assets	3,658	3,950
Total current assets	146,152	159,504
Restricted cash, non-current	745	745
Marketable debt securities, non-current	19,356	42,336
Property and equipment, net	1,318	759
Operating lease right-of-use asset	2,602	3,174
Other assets	5,920	2,950
Total assets	176,093	209,468
Current liabilities:
Accounts payable	4,663	3,468
Accrued expenses and other current liabilities	7,370	6,229
Operating lease liability	1,286	1,242
Total current liabilities	13,319	10,939
Operating lease liability, non-current	1,463	2,117
Total liabilities	14,782	13,056
Commitments and contingencies (Note 9)
Stockholders’ Equity:
Series 1 Convertible Preferred Stock, 8,028 shares authorized at June 30, 2026 and December 31, 2025, 872 and 5,615 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
Common stock, 59,083,935 and 53,587,260 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	59	54
Additional paid-in capital	503,484	498,687
Accumulated deficit	(341,869)	(302,419)
Accumulated other comprehensive income (loss)	(363)	90
Total stockholders’ equity	161,311	196,412
Total liabilities and stockholders’ equity	$ 176,093	$ 209,468

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Operating expenses:
Research and development	$ 16,955	$ 10,770	$ 30,517	$ 19,918
General and administrative	6,369	5,816	12,436	10,792
Total operating expenses	23,324	16,586	42,953	30,710
Income (Loss) from operations	(23,324)	(16,586)	(42,953)	(30,710)
Other income (expense), net:
Interest and investment income (expense)	1,656	1,626	3,503	3,355
Other income (expense)				481
Other income (expense), net	1,656	1,626	3,503	3,836
Net income (loss)	(21,668)	(14,960)	(39,450)	(26,874)
Other comprehensive income (loss):
Net unrealized gain (loss) on marketable debt securities	1	(12)	(453)	75
Other comprehensive income (loss)	1	(12)	(453)	75
Comprehensive income (loss)	$ (21,667)	$ (14,972)	$ (39,903)	$ (26,799)
Net income (loss) per share attributable to common stockholders, basic (in Dollars per share)	$ (0.36)	$ (0.35)	$ (0.67)	$ (0.65)
Net income (loss) per share attributable to common stockholders, diluted (in Dollars per share)	$ (0.36)	$ (0.35)	$ (0.67)	$ (0.65)
Weighted-average shares outstanding, basic (in Shares)	61,006,766	42,270,855	59,282,380	41,493,714
Weighted-average shares outstanding, diluted (in Shares)	61,006,766	42,270,855	59,282,380	41,493,714

Accrued Expenses and Other Current Liabilities

6 Months Ended

Jun. 30, 2026

Accrued Expenses and Other Current Liabilities [Abstract]

Accrued Expenses and Other Current Liabilities

7. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following:

	As of
	June 30, 2026		December 31, 2025
Research and development	$	4,149	$	2,683
Employee costs		2,690		3,267
Other expenses		531		279
Total	$	7,370	$	6,229

Prepaid Expenses and Other Current Assets

6 Months Ended

Jun. 30, 2026

Prepaid Expenses and Other Current Assets [Abstract]

Prepaid Expenses and Other Current Assets

5. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:

	As of
	June 30, 2026		December 31, 2025
Prepaid research and development	$	1,079	$	1,926
Accrued interest on marketable debt securities		1,277		1,257
Proceeds in transit in connection with stock option exercise		412		-
Prepaid insurance		166		355
Prepaid software		253		115
Other prepaid expenses		241		232
Other current assets		230		65
Total	$	3,658	$	3,950

Insider Trading Arrangements

3 Months Ended

Jun. 30, 2026

Trading Arrangements, by Individual

Material Terms of Trading Arrangement

The following table provides information concerning Rule 10b5-1 trading arrangements (as defined in Item 408 of Regulation S-K under the Exchange Act) adopted, modified, or terminated in the three months ended June 30, 2026 by any director or any executive officer who is subject to the filing requirements of Section 16 of the Exchange Act. These trading arrangements are intended to satisfy the affirmative defense of Rule 10b5-1(c). These trading arrangements permit transactions through and including the earlier to occur of (a) the completion of all purchases or sales or (b) the date listed in the table below. These trading arrangements, identified as “Rule 10b5-1 Trading Arrangements”, only permit transactions upon expiration of the applicable mandatory cooling-off period under Rule 10b5-1.

Name (Title)

Action Taken
(Date of Action)

Nature of
Trading
Arrangement

Type of
Trading
Arrangement

Duration of
Trading
Arrangement

Aggregate Number
of Securities

Jesse Shefferman

(President, Chief Executive Officer and Director)

Terminated^(a)

(June 26, 2026)

Sale

Rule 10b5-1
trading
arrangement

June 16, 2026 –
April 28, 2028

754,054

Jesse Shefferman

(President, Chief Executive Officer and Director)

Adopted^(a)

(June 26, 2026)

Sale

Rule 10b5-1
trading
arrangement

September 25, 2026 –
April 28, 2028

540,364

Jacqueline Zummo

(Chief R&D Officer)

Adopted

(June 25, 2026)

Sale

Rule 10b5-1
trading
arrangement

September 24, 2026 –
June 30, 2028

372,893

(a)	On June 26, 2026, Jesse Shefferman modified a Rule 10b5-1 trading arrangement originally adopted on March 17, 2026. Pursuant to Rule 10b5-1, the modification was deemed a termination of the prior arrangement and the adoption of a new Rule 10b5-1 trading arrangement.

June 16, 2026 – April 28, 2028 [Member] | Jesse Shefferman [Member]

Trading Arrangements, by Individual

Name

Jesse Shefferman

Title

President, Chief Executive Officer and Director

Rule 10b5-1 Arrangement Terminated

true

Termination Date

June 26, 2026

Aggregate Available

754,054

September 25,2026 – April 28, 2028 [Member] | Jesse Shefferman [Member]

Trading Arrangements, by Individual

Name

Jesse Shefferman

Title

President, Chief Executive Officer and Director

Rule 10b5-1 Arrangement Adopted

true

Adoption Date

June 26, 2026

Aggregate Available

540,364

September 24, 2026 – June 30, 2028 [Member] | Jacqueline Zummo [Member]

Trading Arrangements, by Individual

Name

Jacqueline Zummo

Title

Chief R&D Officer

Rule 10b5-1 Arrangement Adopted

true

Adoption Date

June 25, 2026

Aggregate Available

372,893

Marketable Debt Securities - Schedule of Interest and Investment Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Schedule of Interest and Investment Income [Abstract]
Interest income	$ 1,480	$ 1,223	$ 3,136	$ 2,778
Accretion of discount (Amortization of premium), net	170	389	353	555
Dividend income	6	14	14	22
Total	$ 1,656	$ 1,626	$ 3,503	$ 3,355

- Definition

Amount of operating dividend income on securities.

+ References + Details

Fair Value of Financial Instruments - Schedule of Financial Instruments that are Measured and Carried at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)
$ in Thousands

Jun. 30, 2026

Dec. 31, 2025

Cash and cash equivalents:

Money market funds

^[1]

$ 16,565

$ 45,355

Corporate bonds

^[1]

3,704

Restricted cash, non-current:

Money market funds

^[2]

745

Marketable debt securities:

Corporate bonds

^[3]

128,810

125,682

Commercial paper

^[3]

10,962

U.S. Treasury securities

^[3]

5,002

22,551

Total

162,084

198,037

Level 1 [Member]

Cash and cash equivalents:

Money market funds

^[1]

16,565

45,355

Corporate bonds

^[1]

Restricted cash, non-current:

Money market funds

^[2]

745

Marketable debt securities:

Corporate bonds

^[3]

Commercial paper

^[3]

U.S. Treasury securities

^[3]

5,002

22,551

Total

22,312

68,651

Level 2 [Member]

Cash and cash equivalents:

Money market funds

^[1]

Corporate bonds

^[1]

3,704

Restricted cash, non-current:

Money market funds

^[2]

Marketable debt securities:

Corporate bonds

^[3]

128,810

125,682

Commercial paper

^[3]

10,962

U.S. Treasury securities

^[3]

Total

139,772

129,386

Level 3 [Member]

Cash and cash equivalents:

Money market funds

^[1]

Corporate bonds

^[1]

Restricted cash, non-current:

Money market funds

^[2]

Marketable debt securities:

Corporate bonds

^[3]

Commercial paper

^[3]

U.S. Treasury securities

^[3]

Total

[1]	Money market funds and corporate bonds with original maturities of 90 days or less are included within cash and cash equivalents in the condensed consolidated balance sheets.
[2]	Restricted money market funds are included within restricted cash, non-current in the condensed consolidated balance sheets.
[3]	Corporate bonds, commercial paper and U.S. Treasury securities with original maturities greater than 90 days are included within marketable debt securities in the condensed consolidated balance sheets and classified as current or non-current based upon whether the maturity of the financial asset is less than or greater than 12 months.

Fair Value of Financial Instruments

6 Months Ended

Jun. 30, 2026

Fair Value of Financial Instruments [Abstract]

Fair Value of Financial Instruments

3. Fair Value of Financial Instruments

The following tables present the Company’s financial assets and liabilities that are measured and carried at fair value and indicate the level within the fair value hierarchy of valuation techniques it utilizes to determine such fair value. The accounting policies of fair value measurements are the same as those described in Part II, Item 8, “Financial Statements and Supplementary Data—Summary of Significant Accounting Policies” in the Company’s Annual Report on Form 10-K:

	As of June 30, 2026
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents:
Money market funds^(a)	$	16,565	$	-	$	-	$	16,565
Restricted cash, non-current:
Money market funds^(b)		745		-		-		745
Marketable debt securities:
Corporate bonds^(c)		-		128,810		-		128,810
Commercial paper^(c)		-		10,962		-		10,962
U.S. Treasury securities^(c)		5,002		-		-		5,002
Total	$	22,312	$	139,772	$	-	$	162,084

	As of December 31, 2025
	Level 1		Level 2		Level 3		Total
Cash and cash equivalents:
Money market funds^(a)	$	45,355	$	-	$	-	$	45,355
Corporate bonds^(a)		-		3,704		-		3,704
Restricted cash, non-current:
Money market funds^(b)		745		-		-		745
Marketable debt securities:
Corporate bonds^(c)		-		125,682		-		125,682
U.S. Treasury securities^(c)		22,551		-		-		22,551
Total	$	68,651	$	129,386	$	-	$	198,037

(a)	Money market funds and corporate bonds with original maturities of 90 days or less are included within cash and cash equivalents in the condensed consolidated balance sheets.

(b)	Restricted money market funds are included within restricted cash, non-current in the condensed consolidated balance sheets.

(c)

Money market funds and U.S. Treasury securities are classified as Level 1 within the fair value hierarchy, because they are valued using quoted prices in active markets. Corporate bonds classified as Level 2 within the fair value hierarchy are valued on the basis of prices from an orderly transaction between market participants provided by reputable dealers or pricing services. Prices of these securities are obtained through independent, third-party pricing services and include market quotations that may include both observable and unobservable inputs. In determining the value of a particular investment, pricing services may use certain information with respect to transactions in such investments, quotations from dealers, pricing matrices and market transactions in comparable investments and various relationships between investments. There were no transfers of financial instruments among Level 1, Level 2, and Level 3 during the period presented.

Cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities at June 30, 2026 and December 31, 2025 are carried at amounts that approximate fair value due to their short-term maturities.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities:
Net income (loss)	$ (39,450)	$ (26,874)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Stock-based compensation	2,746	1,736
Operating lease right-of-use asset	572	530
Depreciation	162	181
Amortization of premium (Accretion of discount) on marketable debt securities	(359)	(532)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	704	(1,012)
Other assets	(2,970)	204
Accounts payable	1,332	1,484
Accrued expenses and other current liabilities	1,141	(2,145)
Operating lease liabilities	(610)	(535)
Net cash provided by (used in) operating activities	(36,732)	(26,963)
Cash flows from investing activities:
Purchase of marketable debt securities	(63,090)	(117,511)
Proceeds from maturity and redemption of marketable debt securities	66,455	11,500
Purchase of property and equipment	(332)	(66)
Net cash provided by (used in) investing activities	3,033	(106,077)
Cash flows from financing activities:
Proceeds from exercise of Underwriters’ Option in December 2024 Public Offering, net of offering costs of $214		2,528
Offering costs paid in connection with public offerings	(526)	(614)
Taxes paid related to net share settlement of restricted stock units	(298)	(185)
Proceeds from exercise of stock options		8
Net cash provided by (used in) financing activities	1,118	1,738
Net increase (decrease) in cash and cash equivalents and restricted cash	(32,581)	(131,302)
Cash and cash equivalents and restricted cash - beginning of period	50,402	163,543
Cash and cash equivalents and restricted cash - end of period	17,821	32,241
Supplemental disclosure of non-cash investing and financing activities:
Proceeds from exercise of stock options included in other current assets and additional paid-in-capital	412
Purchase of property and equipment included in accounts payable and property and equipment	389
Reconciliation of cash and cash equivalents and restricted cash to the condensed consolidated balance sheets:
Cash and cash equivalents	17,076	31,496
Restricted cash, non-current	745	745
Cash and cash equivalents and restricted cash	17,821	32,241
Pre-funded Warrants
Cash flows from financing activities:
Proceeds from exercise of warrants		1
Common Warrants
Cash flows from financing activities:
Proceeds from exercise of warrants	$ 1,942

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) (Parentheticals) $ in Thousands	3 Months Ended
	Mar. 31, 2025 USD ($)
Statement of Stockholders' Equity [Abstract]
Public offering, net of offering costs	$ 214

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2026	Jun. 12, 2026	Jun. 11, 2026	Dec. 31, 2025
Statement [Line Items]
Preferred stock, par value (in Dollars per share)	$ 0.001			$ 0.001
Preferred stock, shares authorized (in Shares)	10,000,000			10,000,000
Common stock, par value (in Dollars per share)	$ 0.001			$ 0.001
Common stock, shares authorized (in Shares)	200,000,000	200,000,000	100,000,000	100,000,000
Common stock, shares issued (in Shares)	59,083,935			53,587,260
Common stock, shares outstanding (in Shares)	59,083,935			53,587,260
Series 1 Convertible Preferred Stock
Statement [Line Items]
Preferred stock, shares authorized (in Shares)	8,028			8,028
Preferred stock, shares issued (in Shares)	872			5,615
Preferred stock, shares outstanding (in Shares)	872			5,615

Accrued Expenses and Other Current Liabilities (Tables)

6 Months Ended

Jun. 30, 2026

Accrued Expenses and Other Current Liabilities [Abstract]

Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following:

	As of
	June 30, 2026		December 31, 2025
Research and development	$	4,149	$	2,683
Employee costs		2,690		3,267
Other expenses		531		279
Total	$	7,370	$	6,229

Prepaid Expenses and Other Current Assets (Tables)

6 Months Ended

Jun. 30, 2026

Prepaid Expenses and Other Current Assets [Abstract]

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:

	As of
	June 30, 2026		December 31, 2025
Prepaid research and development	$	1,079	$	1,926
Accrued interest on marketable debt securities		1,277		1,257
Proceeds in transit in connection with stock option exercise		412		-
Prepaid insurance		166		355
Prepaid software		253		115
Other prepaid expenses		241		232
Other current assets		230		65
Total	$	3,658	$	3,950

Stockholders’ Equity

6 Months Ended

Jun. 30, 2026

Stockholders’ Equity [Abstract]

Stockholders’ Equity

10. Stockholders’ Equity

Common Stock

As of June 30, 2026 and December 31, 2025, the Company had 200,000,000 and 100,000,000 shares of common stock authorized for issuance, respectively, $0.001 par value per share, of which 59,083,935 and 53,587,260 shares were issued and outstanding, respectively.

On June 12, 2026, the stockholders approved an amendment to the Company’s sixth amended and restated certificate of incorporation to increase the number of authorized shares of common stock to 200,000,000 from 100,000,000.

The holders of the Company’s common stock are entitled to one vote per share.

On May 13, 2026, the Company entered into a sales agreement with TD Securities (USA) LLC, as sales agent, pursuant to which the Company may offer and sell, from time to time, shares of the Company’s common stock having an aggregate offering price of up to $100,000, or the ATM Program. During the three and six months ended June 30, 2026, the Company did not sell any shares under the ATM Program.

Preferred Stock

As of June 30, 2026 and December 31, 2025, the Company had 10,000,000 shares of preferred stock authorized for issuance, $0.001 par value per share, of which 8,028 shares of Series 1 Convertible Preferred Stock were authorized for issuance and 872 and 5,615 shares were issued and outstanding as of June 30, 2026 and December 31, 2025, respectively. Each share of Series 1 Convertible Preferred Stock is convertible into approximately 1,000 shares of common stock, at a conversion price initially equal to approximately $7.01 per common share, subject to certain adjustments as described in the certificate of designation of preferences, rights and limitations of Series 1 Convertible Preferred Stock.

During the three and six months ended June 30, 2026, approximately 3,772 and 4,743 shares of Series 1 Convertible Preferred Stock, respectively, were converted into 3,773,586 and 4,744,790 shares of common stock, respectively.

The holders of Series 1 Convertible Preferred Stock are not entitled to vote.

Warrants

In connection with the April 2024 private placement, or the April 2024 Private Placement, the Company issued common warrants, or the April 2024 Common Warrants, to purchase an aggregate of up to 10,843,380 shares of the Company’s common stock. Pursuant to the terms of issuance, the April 2024 Common Warrants were exercisable on or prior to the earlier of: (i) April 10, 2027 or (ii) 90 days after the public announcement that the Company has demonstrated a six-month complete response rate of minimum 42% from at least 25 BCG-Unresponsive (where BCG is defined as Bacillus Calmette-Guérin) patients in the ADVANCED-2 (Cohort B) clinical trial, at an exercise price of $5.25 per share. On March 30, 2026, the Company publicly announced that it had satisfied the condition set forth for fixing the termination date for exercise of the April 2024 Common Warrants, and as such, the unexercised April 2024 Common Warrants expired on June 29, 2026.

In connection with the April 2024 Private Placement, for certain purchasers, the Company issued pre-funded warrants, or the April 2024 Pre-Funded Warrants, to purchase an aggregate of up to 1,700,000 shares of the Company’s common stock. The April 2024 Pre-Funded Warrants are exercisable at any time.

In connection with the December 2024 public offering, or the December 2024 Public Offering, for certain purchasers, the Company issued pre-funded warrants, or the December 2024 Pre-Funded Warrants, to purchase an aggregate of up to 2,325,372 shares of the Company’s common stock. The December 2024 Pre-Funded Warrants are exercisable at any time.

The following is a summary of the activity of the Company’s warrants to acquire shares of common stock for the six months ended June 30, 2026:

Equity Instrument	Outstanding, December 31, 2025		Granted		Exercised		Expired		Outstanding, June 30, 2026		Exercise Price per Share
April 2024 Common Warrants		10,118,380		-		370,000		9,748,380		-	$	5.250
April 2024 Pre-Funded Warrants		1,700,000		-		-		-		1,700,000	$	0.001
December 2024 Pre-Funded Warrants		1,700,272		-		-		-		1,700,272	$	0.001
Total		13,518,652		-		370,000		9,748,380		3,400,272

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479951/505-20-S50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479982/505-20-S25-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479951/505-20-S50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S25
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479982/505-20-S25-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481520/505-30-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 1.D.2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479921/505-20-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479951/505-20-S50-3

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 1.B.3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480148/855-10-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S25
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479982/505-20-S25-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-5

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

+ Details

Other Assets (Tables)

6 Months Ended

Jun. 30, 2026

Other Assets [Abstract]

Schedule of Other Assets Consists

Other assets consist of the following:

	As of
	June 30, 2026		December 31, 2025
Prepaid research and development, non-current	$	5,846	$	2,930
Other non-current assets		74		20
Total	$	5,920	$	2,950

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($) $ in Thousands	Series 1 Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Total
Balance at Dec. 31, 2024		$ 35	$ 412,077	$ (244,980)	$ 2	$ 167,134
Balance (in Shares) at Dec. 31, 2024	7,991	35,044,772
Statement [Line Items]
Issuance of common stock upon conversion of Series 1 Preferred Stock		$ 2	(2)
Issuance of common stock upon conversion of Series 1 Preferred Stock (in Shares)	(2,376)	2,376,244
Issuance of common stock upon exercise of pre-funded warrants		$ 1				1
Issuance of common stock upon exercise of pre-funded warrants (in Shares)		625,100
Issuance of common stock from December 2024 Public Offering, net of offering costs of $214		$ 1	2,527			2,528
Issuance of common stock from December 2024 Public Offering, net of offering costs of $214 (in Shares)		438,738
Issuance of common stock upon settlement of restricted stock units			(185)			(185)
Issuance of common stock upon settlement of restricted stock units (in Shares)		92,959
Stock-based compensation - restricted stock units			121			121
Stock-based compensation - stock options			712			712
Unrealized gain (loss) on marketable debt securities					87	87
Net income (loss)				(11,914)		(11,914)
Balance at Mar. 31, 2025		$ 39	415,250	(256,894)	89	158,484
Balance (in Shares) at Mar. 31, 2025	5,615	38,577,813
Balance at Dec. 31, 2024		$ 35	412,077	(244,980)	2	167,134
Balance (in Shares) at Dec. 31, 2024	7,991	35,044,772
Statement [Line Items]
Net income (loss)						(26,874)
Balance at Jun. 30, 2025		$ 39	416,161	(271,854)	77	144,423
Balance (in Shares) at Jun. 30, 2025	5,615	38,581,863
Balance at Mar. 31, 2025		$ 39	415,250	(256,894)	89	158,484
Balance (in Shares) at Mar. 31, 2025	5,615	38,577,813
Statement [Line Items]
Issuance of common stock upon exercise of stock options			8			8
Issuance of common stock upon exercise of stock options (in Shares)		2,842
Issuance of common stock upon settlement of restricted stock units
Issuance of common stock upon settlement of restricted stock units (in Shares)		1,208
Stock-based compensation - restricted stock units			167			167
Stock-based compensation - stock options			736			736
Unrealized gain (loss) on marketable debt securities					(12)	(12)
Net income (loss)				(14,960)		(14,960)
Balance at Jun. 30, 2025		$ 39	416,161	(271,854)	77	144,423
Balance (in Shares) at Jun. 30, 2025	5,615	38,581,863
Balance at Dec. 31, 2025		$ 54	498,687	(302,419)	90	196,412
Balance (in Shares) at Dec. 31, 2025	5,615	53,587,260
Statement [Line Items]
Issuance of common stock upon conversion of Series 1 Preferred Stock		$ 1	(1)
Issuance of common stock upon conversion of Series 1 Preferred Stock (in Shares)	(971)	971,204
Issuance of common stock upon exercise of common warrants			1,942			1,942
Issuance of common stock upon exercise of common warrants (in Shares)		370,000
Issuance of common stock upon settlement of restricted stock units			(272)			(272)
Issuance of common stock upon settlement of restricted stock units (in Shares)		127,118
Stock-based compensation - restricted stock units			317			317
Stock-based compensation - stock options			1,045			1,045
Unrealized gain (loss) on marketable debt securities					(454)	(454)
Net income (loss)				(17,782)		(17,782)
Balance at Mar. 31, 2026		$ 55	501,718	(320,201)	(364)	181,208
Balance (in Shares) at Mar. 31, 2026	4,644	55,055,582
Balance at Dec. 31, 2025		$ 54	498,687	(302,419)	90	196,412
Balance (in Shares) at Dec. 31, 2025	5,615	53,587,260
Statement [Line Items]
Net income (loss)						(39,450)
Balance at Jun. 30, 2026		$ 59	503,484	(341,869)	(363)	161,311
Balance (in Shares) at Jun. 30, 2026	872	59,083,935
Balance at Mar. 31, 2026		$ 55	501,718	(320,201)	(364)	181,208
Balance (in Shares) at Mar. 31, 2026	4,644	55,055,582
Statement [Line Items]
Issuance of common stock upon exercise of stock options			412			412
Issuance of common stock upon exercise of stock options (in Shares)		215,687
Issuance of common stock upon conversion of Series 1 Preferred Stock		$ 4	(4)
Issuance of common stock upon conversion of Series 1 Preferred Stock (in Shares)	(3,772)	3,773,586
Issuance of common stock upon settlement of restricted stock units			(26)			(26)
Issuance of common stock upon settlement of restricted stock units (in Shares)		39,080
Stock-based compensation - restricted stock units			294			294
Stock-based compensation - stock options			1,090			1,090
Unrealized gain (loss) on marketable debt securities					1	1
Net income (loss)				(21,668)		(21,668)
Balance at Jun. 30, 2026		$ 59	$ 503,484	$ (341,869)	$ (363)	$ 161,311
Balance (in Shares) at Jun. 30, 2026	872	59,083,935

Segment Information (Tables)

6 Months Ended

Jun. 30, 2026

Segment Information [Abstract]

Schedule of Reportable Segment and the Significant Expenses, Including Consolidated Net Income (Loss)

The following table sets forth information about the Company’s single reportable segment and the significant expenses reviewed by the CODM, including a reconciliation to consolidated net income (loss):

	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2026			2025			2026			2025
Research and development expenses:
TARA-002 in NMIBC	$	6,848		$	4,898		$	12,686		$	8,455
TARA-002 in LMs		852			477			1,660			1,027
IV Choline Chloride		2,726			1,852			4,946			4,367
Other research and development		6,165			3,317			10,449			5,651
General and administrative expenses		5,349			5,139			10,466			9,474
Stock-based compensation expense		1,384			903			2,746			1,736
Income (loss) from operations		(23,324	)		(16,586	)		(42,953	)		(30,710	)
Other income (expense), net		1,656			1,626			3,503			3,836
Segment net income (loss)		(21,668	)		(14,960	)		(39,450	)		(26,874	)
Adjustments and reconciling items		-			-			-			-
Net income (loss)	$	(21,668	)	$	(14,960	)	$	(39,450	)	$	(26,874	)

- Definition

Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

+ Details

Segment Information - Schedule of Reportable Segment and the Significant Expenses, Including Consolidated Net Income (Loss) (Details) - Reportable Segment [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Research and development expenses:
General and administrative expenses	$ 5,349	$ 5,139	$ 10,466	$ 9,474
Stock-based compensation expense	1,384	903	2,746	1,736
Income (loss) from operations	(23,324)	(16,586)	(42,953)	(30,710)
Other income (expense), net	1,656	1,626	3,503	3,836
us-gaap:NetIncomeLoss	(21,668)	(14,960)	(39,450)	(26,874)
Adjustments and reconciling items
Net income (loss)	(21,668)	(14,960)	(39,450)	(26,874)
TARA-002 in NMIBC [Member]
Research and development expenses:
Research and development expenses	6,848	4,898	12,686	8,455
TARA-002 in LMs [Member]
Research and development expenses:
Research and development expenses	852	477	1,660	1,027
IV Choline Chloride [Member]
Research and development expenses:
Research and development expenses	2,726	1,852	4,946	4,367
Other research and development [Member]
Research and development expenses:
Research and development expenses	$ 6,165	$ 3,317	$ 10,449	$ 5,651

Segment Information

6 Months Ended

Jun. 30, 2026

Segment Information [Abstract]

Segment Information

13. Segment Information

The Company’s Chief Executive Officer is the chief operating decision maker, or CODM. The CODM allocates resources and assesses performance of the Company’s single reportable segment by regularly reviewing the segment net income (loss) that also is reported on the condensed consolidated statements of operations and comprehensive loss as consolidated net income (loss). The measure of segment assets is reported on the balance sheet as total consolidated assets.

	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2026			2025			2026			2025
Research and development expenses:
TARA-002 in NMIBC	$	6,848		$	4,898		$	12,686		$	8,455
TARA-002 in LMs		852			477			1,660			1,027
IV Choline Chloride		2,726			1,852			4,946			4,367
Other research and development		6,165			3,317			10,449			5,651
General and administrative expenses		5,349			5,139			10,466			9,474
Stock-based compensation expense		1,384			903			2,746			1,736
Income (loss) from operations		(23,324	)		(16,586	)		(42,953	)		(30,710	)
Other income (expense), net		1,656			1,626			3,503			3,836
Segment net income (loss)		(21,668	)		(14,960	)		(39,450	)		(26,874	)
Adjustments and reconciling items		-			-			-			-
Net income (loss)	$	(21,668	)	$	(14,960	)	$	(39,450	)	$	(26,874	)

Other research and development expenses consist of personnel-related expenses as well as other external research and development expenses that are not directly attributable to a specific program.

- Definition

The entire disclosure for segment reporting.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 18: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 19: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 21: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

+ Details